Management of cutaneous side effects of cetuximab therapy with vitamin K1 crème

Radiology and Oncology

Volumn 42, Issue 4, 2008, Pages 215-224

  Ocvirk, Janja ^a   Rebersek, Martina ^a  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

Cetuximab; Colorectal cancer; Cutaneous side effects; Vitamin K1 cr me

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CLINDAMYCIN; CORTICOSTEROID DERIVATIVE; ERYTHROMYCIN; FLUOROURACIL; FOLINIC ACID; HISTAMINE H1 RECEPTOR ANTAGONIST; IRINOTECAN; OXALIPLATIN; PHYTOMENADIONE; PLACEBO; RECONVAL K1; UNCLASSIFIED DRUG; UREA;

ACNE; ALOPECIA; ANUS FISSURE; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL FEATURE; CLINICAL TRIAL; COLORECTAL CANCER; CONJUNCTIVITIS; CONTROLLED STUDY; DEHYDRATION; DESQUAMATION; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; DYSPHAGIA; FEMALE; FEVER; FOLLOW UP; HUMAN; HYPERPIGMENTATION; HYPERTRICHOSIS; HYPOMAGNESEMIA; INTERSTITIAL LUNG DISEASE; KIDNEY FAILURE; LEUKOPENIA; LUNG EMBOLISM; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; METASTASIS; MUCOSA INFLAMMATION; NAIL DISEASE; NAUSEA AND VOMITING; PARONYCHIA; PROGRESSION FREE SURVIVAL; PRURITUS; RADIATION DERMATITIS; SEPSIS; SIDE EFFECT; SKIN CARE; SKIN MANIFESTATION; SKIN NECROSIS; STOMATITIS; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; UVEITIS;

EID: 58149164701     PISSN: 13182099     EISSN: 15813207     Source Type: Journal    
DOI: 10.2478/v10019-008-0022-4     Document Type: Article

References (30)

1. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002; 7(Suppl 4): 2-8.
2. Moosmann N, Heinemann V. Cetuximab in the treatment of metastatic colorectal cancer. Expert Opin Biol Ther 2007; 7: 243-56.
3. Frieze DA, McCune JS. Current status of cetuximab for the treatment of patients with solid tumors. Ann Pharmacother 2006; 40: 241-50.
4. Summary of product characteristics. http://www.emea.europa.eu/humandocs/ Humans/EPAR/erbitux/ erbitux.htm; 25 November 2008.
5. Smrdel U, Kovač V. Erlotinib in previously treated non-small-cell lung cancer. Radiol Oncol 2006; 40: 39-42.
6. Harding J, Burtness B. Cetuximab: an epidermal growth factor receptor chimeric human-murine monoclonal antibody. Drugs Today 2005; 41: 107-127.
7. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Eng J Med 2004; 351: 337-45.
8. Wilke H, Glynne-Jones R, Thaler J, Adenis A, Preusser P, Aguilar EA, et al. Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study. J Clin Oncol 2008; 26: 5335-43.
9. Scheiuthauer W, Sobrero A, Lenz HJ, Maurel J, Lutz M, Middleton G, et al. Cetuximab plus irinotecan in patients with mCRC who failed prior oxaliplatin-based therapy: the EPIC trial. [Abstract]. Eur J Cancer 2007; 5(4): 235.
10. Van Cutsem E, Nowacki M, Lang I, Cascinu S, Schepotin I, Maurel J, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. ASCO 2007. J Clin Oncol 2007; 25(18 Suppl): Abstract 4000.
11. Bokemeyer C, Staroslawska E, Makhson A, Bondarenko I, Hartmann JT, Shelygin Y, et al. Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): a large-scale phase II study, OPUS. [Abstract]. Eur J Cancer 2007; 5(4): 236.
12. Salz LB, Lenz HJ, Kindler HL, Hochster HS, Wadler S, Hoff PM, et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer. The BOND-2 study. J Clin Oncol 2007; 25: 4516-8.
13. Adam R, Aloia T, Levi F, de Haas RJ, Paule B, Bralet MP, et al. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic treatment. J Clin Oncol 2007; 25: 4593-602.
14. Ciardiello F, Cervantes A, Vega-Villegas ME, Casado E, Rodriguez-Braun E, Martinelli E, et al. Optimal dose for an every 2 week (q2w) cetuximab (C) regimen in patients (pts) metastatic colorectal cancer (mCRC): a phase I safety, pharmacokinetics(PK) and pharmacodynamics (PD) study of weekly (q1w) add q2w schedules. [Abstract]. Eur J Cancer 2007; 5(4): 247.
15. Pfeiffer P, Bjerregaard JK, Qvortrup C, Jensen BV, Yilmaz M, Nielsen D. Simplification of cetuximab (Cet) administration: double dose of every second week as a 60 minute infusion. J Clin Oncol 2007; 25(18 Suppl): Abstract 4133.
16. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Eng J Med 2006; 354: 567-78.
17. Burtness B, Goldwasser MA, Flood W, Mattar B, Forrastiere AA. Phase III randomized trial of cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An eastern Cooperative Oncology Group study. J Clin Oncol 2005; 23: 8646-54.
18. Bourhis J, Rivera F, Mesia R, Awada A, Geoffrois L, Borel C, et al. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2006; 24: 2866-72.
19. Bernier J. Cetuximab in the treatment of head and neck cancer. Expert Rev Anticancer Ther 2006; 6: 1539-52.
20. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-8.
21. Carson EJ, Novak AM, Stella PJ. Hypomagnesemia in patients with stage IV colorectal cancer treated with cetuximab as a single agent. [Abstract 3655]. Proc Am Soc Clin Oncol 2005; 24: 248-54.
22. Vallbohmer D, Lenz HJ. Epidermal growth factor receptor as a target for chemotherapy. Clin Colorectal Cancer 2005; 5(Suppl 1): S19-27.
23. Damjanov N, Meropol NJ. Epidermal growth factor receptor inhibitors for the treatment of colorectal cancer: a promise fulfilled? Oncology 2004; 18: 479-88.
24. Perez- Soler R, Zou Y, Li T, Tornos C, Ling Y. Topical vitamin K3 (Vit K3, Menadione) prevents erlotinib and cetuximab-induced EGFR inhibition in the skin. J Clin Oncol 2006; 24(18 Suppl): Abstract 3036.
25. National Cancer Institute. Common terminology criteria for adverse events v.3.0 http:// ctep.cancer.gov/reporting/ctc.html.
26. Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC. Cutaneous side-effects in cancer patients treated with the epidermal growth factor receptor antibody C225. Br J Dermatol 2001; 144: 1169-76.
27. Segaert1 S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors Ann Oncol 2005; 16: 1425-33.
28. Agero ALC, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC. Dermatological side-effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006; 55: 657-70.
29. Galimont-Collen AFS, Vos LE, Lavrijsen APM, Ouwrkerk J, Gelderblom H. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. Eur J Cancer 2007; 43: 845-51.
30. Velenik V, Oblak I, Anderluh F. Quality of life in patients after combined modality treatment of rectal cancer: Report of a prospective phase II study. Radiol Oncol 2008: 42: 207-14.